Source link : https://www.newshealth.biz/health-news/novel-pcsk9-drives-high-risk-patients-to-target-ldl/
LYON, France — Lerodalcibep, a novel, third-generation anti–proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, helps high-risk patients already receiving maximally tolerated statins to achieve guideline lipid targets, reported investigators. In the randomized, placebo-controlled LIBerate-CVD trial of more than 900 patients, lerodalcibep led to reductions from baseline in low-density lipoprotein (LDL) cholesterol levels of more than […]
Author : News Health
Publish date : 2024-06-25 09:48:40
Copyright for syndicated content belongs to the linked Source.
Categories